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1. Introduction
Magnetic resonance imaging (MRI) has become a prominent 
non- or low-invasive imaging technique for disease diagnosis.1,2 
Low-molecular-weight contrast agents (CAs), such as Gd-DTPA 
(DTPA = diethylenetriaminepentaacetic acid) and Gd-DOTA 
(DOTA = 1,4,7,10-tetraazacyclododecane-1,4,7,10-tetraacetic 
acid), are widely used in the clinical diagnosis of tumors (Figure 
1).3-8
However, the low contrast efficiency, non-specific retention 
and rapid clearance of these low-molecular-weight CAs in the 
body necessitate a high dosage (ca. 0.5 M), which imposes a 
great physical strain and can lead to side effects in the patient, 
such as osmotic shock.9,10  The main reason for their low contrast 
efficiency is that up to eight of the nine coordination sites of Gd 
are firmly occupied with ionic chelating ligands, and only one 
site remains available for coordination with free water molecules, 
which can be observed by MRI. In addition, Gd metal could 
rotate quite rapidly at the center of small ligands, and 
enhancement of the image contrast would be reduced. 
Therefore, there is a strong need for the development of highly 
sensitive Gd-MRI CAs, and recently there has been growing 
worldwide interest in the development of Gd-MRI CAs that 
consist of Gd-functionalized dendrimers11-15 and other 
macromolecules.16-19  Dendrimers20-23 are a unique category of 
macromolecules with well-controlled sizes, nanoscopic 
dimensions, and numerous peripheral chemical groups to which 
Gd chelates can be coupled.  Gd-functionalized poly(amido-
amine) (PAMAM)24-27 and poly(propyleneimine) (PPI)28-30 
dendrimers have been reported and evaluated in animal models 
for high-resolution MRI, in which dendrimers were used as a 
core and Gd chelates were positioned in the periphery.31-33  
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Novel chiral dendrimer-triamine-coordinated Gd complexes with polyaminoalcohol end groups 
were synthesized and shown to have longitudinal relaxivity (r1) values 5 times higher than that 
of clinically used Gd-DTPA. The affinities of Gd-4a and Gd-4b for bovine serum albumin 
(BSA), respectively, were estimated by a quartz crystal microbalance (QCM) measurement.  The 
amino groups of the dendrimer were then conjugated with PEG. This conjugation with PEG 
strongly affected its ability to attenuate signals in T1-weighted MRI. 
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Figure 1. Structures of Gd-DTPA and Gd-DOTA. 
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Unfortunately, among the Gd-functionalized dendrimers that 
have been reported for use as contrast agents, dendrimers were 
only used to slow the molecular tumbling and rotation of Gd.  
The intravascular retention time is prolonged, but the principle of 
reducing the 1H relaxation time of a water molecule is the same 
as that with low-molecular-weight contrast agents. 
We previously reported the synthesis and functional 
evaluation of a chiral 2nd-generation dendrimer-triamine-
coordinated Gd complex with polyol end groups as a highly 
sensitive CA for MRI (Figure 2).34, 35 
In that report, we synthesized chiral dendrimer-triamine-
coordinated Gd-MRI CAs and clarified the pharmacokinetic 
differences between the optical isomers, Gd-2a and Gd-2b. The 
synthesized Gd-MRI CAs were shown to have longitudinal 
relaxivity (r1) values 3 times higher than that of clinically used 
Gd-DTPA. The pharmacokinetic differences between optical 
isomers were estimated based on T1-weighted MR images of 
mice before and after the intravenous injection of Gd-2a and Gd-
2b. As a result, Gd-2a is retained in the vasculature for a longer 
time after administration. 
Although the conjugation of polyethylene glycol (PEG) and/or 
antibodies with CAs might be needed to achieve specific 
targetability in vivo, such as for cancers, polyol end groups in 
Gd-2a or Gd-2b did not seem to be suitable for conjugation 
under physiological conditions. In this paper, based on this 
preparation of 2nd-generation dendrimer-triamine-coordinated 
CAs, we tried to replace these hydroxyl end groups with amino 
end groups for the easy introduction of PEG and antibodies.  We 
synthesized novel highly sensitive chiral and racemic dendrimer-
triamine-coordinated Gd complexes with polyaminoalcohol end 
groups, Gd-4a, Gd-4b and Gd-4 (racemic) (Figure 3), and 
evaluated their function as Gd-MRI CAs. The amino end groups 
of the dendrimer CAs were conjugated with a PEG chain, and the 
functions of the resulting complex were evaluated in vitro.  
2. Results and discussions 
2.1. Synthesis of chiral dendrimer-triamine-coordinated Gd-MRI 
CAs with polyaminoalcohol end groups, Gd-4a and Gd-4b 
(R)- and (S)-chiral dendrimer-triamine ligands with polyol end 
groups were synthesized by the previously reported method.34, 35   
According to Scheme 1, 2nd-generation dendrimer Gd-MRI CAs 
with polyaminoalcohol end groups, Gd-4a and Gd-4b, were 
synthesized. (R)- and (S)-chiral dendrimer-triamine ligands with 
polyol end groups, 2a and 2b, were epoxidated with 
trimethylsilyl chloride and trimethyl orthoacetate.38 A ring-
opening reaction of the epoxide groups with ammonium 
hydroxide was performed and novel chiral dendrimer-triamine-
coordinated Gd complexes, Gd-4a and Gd-4b, were obtained 
after complexation with gadolinium trichloride (GdCl3·6H2O). 
2.2. Synthesis of a racemic dendrimer-triamine-coordinated Gd-
MRI CA with polyaminoalcohol end groups, Gd-4 (racemic) 
According to Scheme 2, a racemic dendrimer Gd-MRI CA 
with polyaminoalcohol end groups Gd-4 (racemic) was 
synthesized. The dendron with olefin ends 8 was synthesized and 
the olefin was epoxidated with meta-chloroperoxybenzoic acid 
(mCPBA) to give 9. After the conjugation of dendron with 
epoxide end groups 9 was conjugated with 1,4,7-
triazacyclononane (TACN) to give 10, a ring-opening reaction of 
the epoxide groups with ammonium hydroxide was performed to 
give 4 (racemic), and novel chiral dendrimer-triamine-
coordinated Gd complexes Gd-4 (racemic) were obtained after 
complexation with GdCl3·6H2O. 
2.3. Synthesis of Boc-protected dendrimer-triamine-coordinated 
Gd-MRI CA,Gd-4-Boc 
The six amino groups of dendrimer ligand 4 (racemic) were 
protected with tert-butoxycarbonyl (Boc) groups and subsequent 
complexation with GdCl3·6H2O gave Gd-4-Boc. 
2.4. Synthesis of PEG-dendrimer-triamine-coordinated Gd-MRI 
CA, Gd-4a-PEG 
The conjugation of 4a with PEG bearing an activated ester 
group (average molecular weight: 5,000) was carried out, and the 
reactant was purified by GPC. Subsequent complexation with 
GdCl3·6H2O gave Gd-4a-PEG. 
2.5. Evaluation of synthesized Gd-MRI CAs, Gd-4 (racemic), Gd-



































Figure 2. Structure of a chiral dendrimer-triamine-coordinated Gd- 

































Figure 3. Structure of novel chiral dendrimer-triamine-coordinated 














Figure 4. T1-weighted MR images of Gd-DTPA, GdCl3·6H2O, Gd-
2a, Gd-4 (racemic), Gd-4a, Gd-4b, Gd-4a-PEG (0.25 mM) and water 
(Spin echo from TR/TE 200/6.2 ms, 7 T, 20 oC). 
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The longitudinal relaxivity (r1) values of dendrimer CAs, 
GdCl3·6H2O, and Gd-DTPA were measured (Figure 4, Table 1).  
 
Table 1. Longitudinal relaxivities (r1) of Gd-
DTPA, GdCl3·6H2O, Gd-4 (racemic), Gd-4a, Gd-
4b, Gd-2a and Gd-4a-PEG. 
 











The r1 values of 2nd-generation dendrimer CAs with 
polyaminoalcohol end groups Gd-4 (racemic), Gd-4a and Gd-4b 
were 19.4 mM-1s-1, 21.5 mM-1s-1, and 20.1 mM-1s-1 respectively, 
which were approximately 5 times larger than that of Gd-DTPA 
(r1 = 3.9 mM-1s-1).  Moreover, the r1 values of 2nd-generation 
dendrimer CAs with polyaminoalcohol end groups Gd-4 
(racemic), Gd-4a and Gd-4b were higher than that of 2nd-
generation dendrimer CA with polyol end groups Gd-2a  (r1 = 
11.4 mM-1s-1). As mentioned previously, established low-
molecular-weight Gd contrast agents such as Gd-DTPA and Gd-
DOTA have ionic chelating ligands that strongly suppress eight 
of the nine coordination sites of Gd. On the other hand, the novel 
Gd complexes have a triamine ligand and three chloride ligands, 
which stably occupy six coordination sites of Gd. Accordingly, 
three coordination sites remain for water molecules, and thus the 
present Gd complexes show longitudinal relaxivity values that 
are 5 times higher than that of Gd-DTPA. 
Figure 5 shows the cytotoxicities of Gd-4 (racemic), Gd-2a, 
and Gd-DTPA toward L929 cells.39 The result indicated that 
dendrimer CAs with polyaminoalcohol end groups Gd-4 
(racemic) were cytotoxic at a concentration at which dendrimer 
CA with polyol end groups Gd-2a and Gd-DTPA were not 
cytotoxic (0.25 mM). This cytotoxicity would be due to the 
primary amino end groups of the dendrimer. Therefore, Boc-
protected 2nd-generation dendrimer CA Gd-4-Boc was 
synthesized and its cytotoxicity was evaluated.  As a result, Boc-
protected dendrimer CA Gd-4-Boc was not cytotoxic, similar to 
Gd-2a and Gd-DTPA.  These observations suggest that the CAs 
conjugated with PEG would have low toxicity and high 
longitudinal relaxivity.  
To anticipate the pharmacokinetic differences between optical 
isomers, the affinities of Gd-4a and Gd-4b for bovine serum 
albumin (BSA), which is a model of plasma protein, were 
estimated by a quartz crystal microbalance (QCM) measurement.  
In sharp contrast to the results of Gd-2a and Gd-2b35 the 
association constant Ka of Gd-4a (1.08×106 M-1) was about 2 
times higher than that of Gd-4b (5.21×105 M-1), which means that 
Gd-4a is retained in the vasculature for a longer time after 
administration in a mouse body. This result was different than 
that with polyol CAs, probably due to the stronger interaction of 
amino groups in Gd-4a and Gd-4b with albumin, which also 
explain the cytotoxicity of Gd-4 (racemic) (Figure 5, vide infra). 
2.6. Evaluation of synthesized PEG-dendrimer Gd-MRI CA, Gd-
4-PEG 
The longitudinal relaxivity (r1) value of PEG-dendrimer CA 
Gd-4-PEG was 52.6 mM-1s-1, which is approximately 13 times 
higher than that of Gd-DTPA and 2.5 times higher than that of 
Gd-4a (Table 1).  In the case of the present PEG-dendrimer CAs, 
the slower molecular tumbling with an increase in molecular 
weight as a result of conjugation with PEG may be responsible 
for the stronger contrast enhancement. 
 
3. Conclusions 
In conclusion, we have synthesized the first chiral dendrimer-
triamine-coordinated Gd contrast agents with polyaminoalcohol 
end groups, and then conjugated these contrast agents with PEG.  
The effects of the molecular weight of PEG on contrast and 
tumor targeting ability in MRI through the EPR (Enhanced and 
Permeability Retention) effect36,37 are now under investigation. 
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Figure 5. Viabilities of L929 cells exposed Gd-DTPA, Gd-1a, Gd-4 
(racemic) and Gd-4-Boc at 0.25 mM. 
Gd-4      Gd-4-Boc    Gd-2a     Gd-DTPA    control 
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4. Experimental section 
4.1. General Methods 
4.1.1. Materials 
All reagents were obtained commercially and used without 
further purification unless otherwise noted. CH3CN (99.8%), 
CHCl3 (99.9%), distilled water, acetone (99%), PPh3 (97.0%), N-
bromosuccinimide (NBS, 99.9%), meta-chloroperoxybenzoic 
acid (mCPBA, 75%), Ce(NH4)2(NO3)6 (CAN, 95%), GdCl3.6H2O, 
1,4-dioxane (99.5%), hexane (99%), KOH (85%), K2CO3 
(99.5%), MgSO4 (99.0%), NaHCO3 (99.5%), methanol (MeOH, 
99.8%), Na2CO3 (99.8%), Na2SO3 (97.0%), Na2SO4 (99.0%), 
tetrahydrofuran (THF), triethylamine (TEA) (98.0%), and BSA 
were purchased from Nacalai Tesque Inc. (Kyoto, Japan).  1.0 M 
Lithium ethoxide in tetrahydrofuran (LiOEt in THF) and 4-
vinylbenzyl chloride (90%) were purchased from Sigma-Aldrich 
Japan K.K. (Tokyo, Japan). 1,4,7-Triazacyclononane (TACN, 
98%), trimethylsilyl chloride (98%) and trimethyl orthoacetate 
(98%) were purchased from Tokyo Chemical Industry Co. Ltd. 
(Tokyo, Japan).  Hydrochloric acid methanolic solution (HCl in 
MeOH, 0.50 mM), 28% NH3 aqueous solution, and dimethyl 
sulfoxide dehydrated (DMSO; 99.0%) were purchased from 
Wako Pure Chemical Industries, Ltd. (Osaka, Japan).  Methylene 
chloride (CH2Cl2) was purchased from Kishida Chemical Co., 
Ltd. (Osaka, Japan). Gd-DTPA was purchased from Bayer 
Holding Ltd. (Tokyo, Japan).  Aluminum oxide 90 active neutral 
was purchased from Merck Chemical Inc. (Darmstadt, Germany).  
Silica gel 60N spherical for flash chromatography was purchased 
from Kanto Chemical Co. Inc. (Tokyo, Japan).  The filter aid 
Celite Standard Super-gel was purchased from Alfa Aesar 
(Lancashire, UK).  Di-tert-butyl dicarbonate was purchased from 
Peptide Institute (Osaka, Japan).  NHS-PEG (SUNBRIGHT ME 
050 AS, Mw 5000) was purchased from NOF Corporation 
(Tokyo, Japan).   
1H-NMR spectra were recorded at 400 MHz, and 13C-NMR 
spectra were recorded at 100 MHz with a JEOL EX400. ESI TOF 
mass spectra were obtained by micrOTOF focus (Bruker 
Daltonics Co., Billerica, MA).  The average molecular weight of 
PEG-conjugated CA was determined by gel permeation 
chromatography (ChromNAV, JASCO Co., Tokyo Japan). The 
concentration of gadolinium was determined by atomic 
absorption spectrometry (AAS Z-2710, Hitachi Ltd., Tokyo, 
Japan) using a gadolinium standard solution (1,000 ppm, 
analytical grade, Wako). Clinically-used Gd-DTPA 
(gadopentetate meglumine) was used as a control for MR 
measurements of the synthesized CAs. 
4.1.2. Relaxation Time Measurements 
Longitudinal relaxivity (r1) was calculated from the relaxation 
time of water proton (T1) with four different concentrations of 
CAs at 20 °C on a Biospec 7.0 T/ 20 USR (Bruker Biospin Inc., 
Billerica, MA) with a 72 mm i.d. Quadrature resonator.   
4.1.3. Cytotoxicity Assay 
Murine L929 fibroblast cells were plated into each well of 96-
multiwell cell culture plates (Corning Inc., Lowell, MA) with 
growth medium (Dulbecco’s modified minimum essential 
medium (DMEM; Life Technologies Japan Ltd., Tokyo, Japan) 
containing 10% of fetal bovine serum (FBS; Sanko Pure 
Chemical Co., Tokyo, Japan), 100 units/ml of penicillin and 0.1 
mg/ml of streptomycin (Sigma-Aldrich Japan K.K., Tokyo, 
Japan) at a density of 1 × 104 cells/cm2.  After incubation for 24 h 
at 37 °C and 5% CO2 - 95% air at atmospheric pressure, the 
medium was replaced by fresh growth medium containing 0.25 
mM of CAs.  After incubation for 48 h under the same condition, 
the cell number was evaluated. After Cell Count Reagent SF (10 
µL, Nacalai Tesque, Kyoto, Japan) was added to each well, plates 
were incubated for 60 min. The absorbance at 450 nm was then 
measured by a spectrophotometer (Versa max, Molecular 
Devices Inc., Union City, CA).  The absorbance was normalized 
by that in cells incubated with growth medium without CA and 
expressed as a cell viability ratio.   
4.1.4. Quartz Crystal Microbalance Analysis 
The ability of CAs to bind to BSA was evaluated with an 
Affinix-QN Pro® system (Initium Inc., Tokyo Japan) according 
to the manufacturer’s instructions.  The dissociation rate constant 
(Kd) was estimated by a global fitting analysis of the saturated 
adsorption amount at each concentration, and the association rate 




























































































































































































Scheme 2.  Synthesis of racemic dendrimer-triamine-coordinated Gd complexes with polyaminoalcohol end groups, Gd-4 (racemic) and Boc-
protected Gd complex, Gd-4-Boc 
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4.2. Synthesis 
4.2.1. Synthesis of 2nd-Generation Dendrimer-triamine-
coordinated Gd-MRI CA with Polyaminoalcohol End Groups 
(Scheme 1) 
4.2.1.1. 2nd-Generation chiral acetonide-triamine dendrimer 
(1a) 
A solution of a LiOEt in THF (1.0 M, 6.0 mL) was added 
dropwise to a solution of TACN (80 mg, 0.62 mmol) in THF (10 
mL) and stirred at 0 °C under Ar. After 10 min, a solution of 2nd-
generation dendron (1.00 g, 1.64 mmol) was added dropwise at 
0 °C, and the mixture was stirred at room temperature for 12 h. 
The mixture was then diluted with 2 × 50 mL of ethyl acetate and 
dried over MgSO4. The solvent was removed under reduced 
pressure, and the residue was purified by flash column 
chromatography (SiO2, CHCl3 : MeOH = 9 : 1) to give 560 mg 
(0.325 mmol, 52%) of 1a as a yellow solid. 1H NMR (400 MHz, 
CDCl3) δ (ppm): 1.48, 1.54 (d, 36H); 2.90 (br, 12H); 3.53-3.56 (q, 
3H); 3.65-3.74 (m, 15H); 4.26-4.30 (m, 6H); 4.35, 4.38 (d, 3H); 
4.45-4.61 (m, 12H); 5.03-5.07 (t, 6H); 7.24-7.33 (m, 36H).  13C 
NMR (100 MHz, CDCl3) δ (ppm): 25.6, 26.2, 70.0, 71.2, 72.5, 
74.4, 77.3, 80.0, 109.2, 125.8, 127.2, 127.4, 129.0, 137.8, 137.8, 
138.0, 138.1. ESI TOF MS: m/z [M+H]+ calcd. for 1721.9377, 
found 1721.9919. Elemental analysis calcd. for 
C105H129N3O18·6H2O: C 68.94, H 7.77, N 2.30, O 20.99; found: C 
69.24, H 7.53, N 2.45, O 20.78.   
4.2.1.2. 2nd-Generation chiral 12-ol-triamine dendrimer (2a)  
A solution of 1a (559 mg, 0.325 mmol) in 0.50 mM 
HCl/MeOH solution (20 mL) was stirred at room temperature for 
4 h.  The reaction was monitored by ESI TOF MS.  After the 
reaction was completed, the solvent was removed under reduced 
pressure to give 478 mg (0.324 mmol, 99%) of 2a as a yellow 
solid. 1H NMR (400 MHz, CD3OD) δ (ppm): 2.81 (br, 12H); 
3.53-3.74 (m 12H); 3.68 (s, 6H); 4.31-4.43 (m, 8H); 4.62-4.64 (m, 
6H); 7.14-7.46 (m, 36H). 13C NMR (100 MHz, CD3OD) δ (ppm): 
50.2, 60.6, 68.7, 71.8, 74.0, 75.4, 75.6, 81.4, 127.4, 128.6, 128.9, 
131.6, 136.1, 138.7, 141.6, 142.7.  ESI TOF MS: m/z [M+H]+ 
calcd. for 1480.7466, found 1480.7818.   
4.2.1.3 2nd-Generation chiral epoxide-triamine dendrimer (3a)  
Trimethylsilyl chloride (5.0 mL, 40 mmol) was added to a 
solution of 2a (300 mg, 0.203 mmol) and trimethyl orthoacetate 
(3.0 mL, 24 mmol) in CH2C12 (3.0 mL) at 0 °C. The solution was 
stirred for 60 min, and then evaporated to obtain crude product.  
It was dissolved in dry methanol (10 mL), and K2CO3 (1.00 g, 
7.25 mmol) was added. The suspension was stirred vigorously 
for 2 h, and then filtered and the residue was washed with CH2Cl2.  
The filtrate was extracted with CH2Cl2 and the organic layer was 
washed with water and brine, dried over MgSO4, and 
concentrated by an evaporator.  The residue was purified by flash 
column chromatography (Al2O3, CHCl3: MeOH = 30 : 1) to 
obtain 3a as a yellow oil (103.4 mg, 75 µmol, 37 %).  1H NMR 
(400 MHz, CDCl3) δ (ppm): 2.76-2.79 (q, 6H); 2.83(s, 12H); 
3.12-3.14 (q, 6H); 3.53-3.56(q, 3H); 3.57 (s, 6H); 3.61-3.75 (q, 
3H); 3.83-3.85 (q, 6H); 4.35-4.38 (d, 2H); 4.47-4.59 (m, 12H); 
7.21-7.32 (m, 36H).  13C NMR (100 MHz, CDCl3) δ (ppm): 51.2, 
52.2, 55.4, 62.7, 70.3, 73.0, 74.9, 80.6, 125.5, 126.9, 127.7, 127.8, 
129.1, 136.8, 137.6, 138.5, 138.6, 140.3.  ESI TOF MS: m/z 
[M+H]+ calcd. for 1372.6832, found 1372.6850. 
4.2.1.4. 2nd-Generation chiral aminoalcohol-triamine dendrimer 
(4a)  
A mixture of 28% NH3 aqueous solution (15.0 mL), 1,4-
dioxane (5.0 mL), and 3a (50.0 mg, 36.5 µmol) was placed in a 
20 mL reaction vial in an Initiator 2.50 microwave reactor at 
200 W, 100 °C, and 14 bar for 60 min.  The solvent was removed 
under reduced pressure to give 30 mg (20.3 µmol, 56%) of 4a as 
a yellow solid.  1H NMR (400 MHz, CD3OD) δ (ppm): 2.79-3.01 
(m, 18H); 3.03-3.05 (m, 6H); 3.44-3.89 (m, 15H); 4.19-4.57 (m, 
18H); 7.03-7.38 (m, 36H). 13C NMR (100 MHz, CD3OD) δ 
(ppm): 47.3, 58.1, 64.4, 70.7, 71.7, 73.9, 75.5, 81.5, 127.0, 128.5, 
129.0, 131.7, 136.3, 139.6, 141.3, 141.8. ESI TOF MS: m/z 
[M+H]+ calcd. for 1474.8425, found 1474.8333. 
4.2.1.5. 2nd-Generation chiral aminoalcohol-triamine dendrimer 
gadolinium complex (Gd-4a)  
A solution of GdCl3·6H2O (82 mg, 225 µmol) in MeOH (2.0 
mL) was added dropwise to a solution of 4a (130 mg, 226 µmol) 
in MeOH (3.0 mL), and the mixture was refluxed under argon for 
48 h. The solvent was removed under reduced pressure to give 
160 mg (190 µmol) of Gd-4a as a yellow solid.  ESI TOF MS: 
m/z [M-Cl]+ 1701.7327.   
4.2.2. Synthesis of 2nd-generation Dendrimer-triamine-
coordinated Gd-MRI CA with Polyaminoalcohol End Groups 
(Scheme 2) 
4.2.2.1. 2nd-Generation dendron of bis(olefin)ether (6) 
To a reaction apparatus equipped with a Dean-Stark tube and 
a reflux cooling tube was added 5 (5.00 g, 18.2 mmol), and the 
inside air was replaced with argon. Subsequently, 4-vinylbenzyl 
chloride (7.5 mL, 56.3 mmol) and 250 mL of toluene were added 
to the reactor under a flow of argon.  The mixture was heated and 
stirred for approximately 30 min to make a uniform solution. To 
the resulting uniform solution was added 6.38 g of KOH to make 
an orange-colored cloudy solution. Thereafter, the solution was 
heated under reflux for 5 h, and then stirred at 100 °C for 12 h.  
After the reaction was completed, the solvent was removed under 
reduced pressure. The crude product was dissolved in CH2Cl2 and 
suction filtration to give a yellow-colored uniform solution.  The 
solvent was removed under reduced pressure, and the residue was 
purified by flash column chromatography (SiO2, CHCl3) to give 
5.13 g (10.2 mmol, 56%) of 6 as a yellow oil. 1H NMR (400 
MHz, CDCl3) δ (ppm): 3.43-3.47 (m, 1H); 3.57-3.65 (m, 4H); 
4.24, 4.27 (d, 1H); 4.36-4.52 (m, 4H); 4.87 (s, 2H); 5.09, 5.11 (d, 
2H); 5.59, 5.63 (d, 2H); 6.54-6.62 (m, 2H); 6.69-6.81 (dd, 4H); 
7.12-7.31 (m, 12H). 13C NMR (100 MHz, CDCl3) δ (ppm): 55.5, 
70.3, 72.9, 74.6, 80.2, 113.5, 114.5, 115.7, 126.0, 127.2, 127.6, 
127.8, 136.5, 136.7, 137.0, 137.8, 138.9, 152.8, 153.9. ESI TOF 
MS: m/z [M+Na]+ calcd. for 529.2349, found 529.2450.   
4.2.2.2. 2nd-Generation dendron of bis(olefin)benzyl alcohol (7) 
A solution of 6 (5.13g, 10.2 mmol) in 1,4-dioxane (40 mL) 
was stirred at 0 °C, and an aqueous solution of CAN (7.35 g, 13.4 
mmol) in 20 mL of water was added dropwise. After the addition 
was completed, the resulting mixture was stirred for 30 min and 
cooled. 150 mL of water was added to stop the reaction. The 
resulting mixture was transferred to a separating funnel and the 
water layer was extracted three times with ethyl acetate. The 
organic layer was collected and washed twice with a 5% K2CO3 
aqueous solution. The washing solution was again washed twice 
with ethyl acetate. The organic layers were all collected and 
washed with a 10% Na2SO3 aqueous solution and then with a 5% 
K2CO3 aqueous solution, dehydrated with brine and MgSO4, and 
concentrated by an evaporator.  The residue was purified by 
column chromatography (SiO2, 100% CHCl3 to 100% ethyl 
acetate) to give 3.06 g (7.65 mmol, 75%) of 7 as an orange oil.  
1H NMR (400 MHz, CDCl3) δ (ppm): 2.27 (br, 1H); 3.42-3.46 (m, 
1H); 3.59-3.88 (m, 1H); 4.23, 4.26 (d, 1H); 4.36-4.48 (m, 4H); 
4.51 (s, 2H); 5.10, 5.12 (d, 2H); 5.59, 5.64 (d, 2H); 6.54-6.62 (m, 
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2H); 7.13-7.26 (m, 12H). 13C NMR (100 MHz, CDCl3) δ (ppm): 
64.7, 70.3, 72.9, 74.6, 80.2, 113.6, 126.0, 127.2, 127.6, 127.8, 
136.4, 136.7, 137.8, 138.4, 140.7.  ESI TOF MS: m/z [M+Na]+ 
calcd. for 423.1931, found 423.2087. 
4.2.2.3. 2nd-Generation dendron of bis(olefin)benzyl bromide (8) 
7 (3.06 g, 7.65 mmol) and 10 mL of CH2Cl2 were added to a 
reactor filled with argon. The reactor was immersed in a cooling 
bath and cooled to 0 °C. PPh3 (2.21 g, 8.42 mmol) and NBS (1.50 
g, 8.42 mmol) were added under a flow of argon, and then the 
mixture was stirred for 12 h. After the reaction was completed, to 
the reaction mixture were added 10 mL of diethyl ether and 20 
mL of saturated Na2CO3 aqueous solution. After the solution was 
separated, the organic layer was dehydrated with brine and 
MgSO4. The resulting organic layer was concentrated by an 
evaporator, and the residue was purified by column 
chromatography (SiO2, ethyl acetate: hexane = 1:3) to give 2.58 g 
(5.58 mmol, 73%) of 8 as an orange oil. 1H NMR (400 MHz, 
CDCl3) δ (ppm): 3.45-3.48 (m, 1H); 3.63-3.68 (m, 1H); 4.27-4.30 
(d, 1H); 4.41-4.53 (m, 6H); 5.13, 5.16 (d, 2H); 5.63, 5.67 (d, 2H); 
6.58-6.66 (m, 2H); 7.14-7.31 (m, 12H). 13C NMR (100 MHz, 
CDCl3) δ (ppm): 33.2, 70.5, 73.0, 74.5, 80.1, 113.7, 126.1, 127.5, 
127.7, 129.1, 136.5, 136.9, 137.4, 137.8, 139.7. ESI TOF MS: 
m/z [M+Na]+ calcd. for 485.1087, 487.1070, found 485.1381, 
487.1363.   
4.2.2.4. 2nd-Generation dendron of bis(epoxide)benzyl bromide 
(9) 
A solution of mCPBA (2.41 g, 14.0 mmol) in CH2Cl2 (2 mL) 
was added dropwise to a solution of 8 (2.58 g, 5.58 mmol) in 
CH2Cl2 (10 mL) at 0 °C, and the mixture was stirred at room 
temperature for 12 h. A saturated Na2SO2 aqueous solution (10 
mL) and a saturated NaHCO3 aqueous solution (10 mL) were 
added to stop the reaction. The mixture was then diluted with 2 × 
10 mL of CH2Cl2 and dried over MgSO4. The solvent was 
removed under reduced pressure, and the residue was purified by 
flash column chromatography (SiO2, CHCl3) to give 772 mg 
(1.56 mmol, 28%) of 9 as a yellow oil. 1H NMR (400 MHz, 
CDCl3) δ (ppm): 2.77-2.79 (m, 2H); 3.12-3.15 (m, 2H); 3.52-3.56 
(m, 1H); 3.69-3.73 (m, 1H); 3.83-3.86 (m, 2H); 4.36, 4.39 (d, 
1H); 4.48-4.61 (m, 6H); 7.23-7.39 (m, 12H). 13C NMR (100 MHz, 
CDCl3) δ (ppm): 33.2, 51.2, 52.2, 70.5, 73.0, 74.6, 80.3, 125.5, 
127.5, 127.9, 129.2, 136.9, 137.5, 138.3, 139.7.  ESI TOF MS: 
m/z [M+Na]+ calcd. for 517.0985, 519.0969, found 517.0993, 
519.0976. 
4.2.2.5. 2nd-Generation epoxide-triamine dendrimer (10) 
A solution of a LiOEt in THF (1.0 M, 2.0 mL) was added 
dropwise to a solution of TACN (201 mg, 1.56 mmol) in THF 
(20 mL), and stirred at 0 °C under argon. After 10 min, a solution 
of 9 (772 mg, 1.56 mmol) was added dropwise at 0 °C, and the 
mixture was stirred at room temperature for 12 h. The mixture 
was then diluted with 2 × 50 mL of ethyl acetate and dried over 
MgSO4. The solvent was removed under reduced pressure, and 
the residue was purified by flash column chromatography (Al2O3, 
CHCl3) to give 620 mg (0.452 mmol, 29%) of 10 as a white solid.  
1H NMR (400 MHz, CDCl3) δ (ppm): 2.76-2.79 (q, 6H); 2.83 (s, 
12H); 3.12-3.14 (q, 6H); 3.53-3.56 (q, 3H); 3.57 (s, 6H); 3.61-
3.75 (q, 3H); 3.83-3.85 (q, 6H); 4.35-4.38 (d, 2H); 4.47-4.59 (m, 
12H); 7.21-7.32 (m, 36H). 13C NMR (100 MHz, CDCl3) δ (ppm): 
51.2, 52.2, 55.4, 62.7, 70.3, 73.0, 74.9, 80.6, 125.5, 126.9, 127.7, 
127.8, 129.1, 136.8, 137.6, 138.5, 138.6, 140.3.  ESI TOF MS: 
m/z [M+H]+ calcd. for 1372.6832, found 1372.6834.   
4.2.2.6. 2nd-Generation- aminoalcohol-triamine dendrimer (4 
(racemic)) 
A mixture of 28% NH3 aqueous solution (3.0 mL), 1,4-
dioxane (1.0 mL) and 10 (119 mg, 225 µmol) was placed in a 2 
mL reaction vial in an Initiator 2.50 microwave reactor at 200 W, 
120 °C, and 12 bar for 60 min. The solvent was removed under 
reduced pressure to give 130 mg (225 µmol, 99%) of 4 (racemic) 
as a yellow solid. 1H NMR (400 MHz, CD3OD) δ (ppm): 2.79-
3.01 (m, 18H); 3.03-3.05 (m, 6H); 3.44-3.89 (m, 15H); 4.19-4.57 
(m, 18H); 7.03-7.38 (m, 36H). 13C NMR (100 MHz, CD3OD) δ 
(ppm): 47.3, 58.1, 64.4, 70.7, 71.7, 73.9, 75.5, 81.5, 127.0, 128.5, 
129.0, 131.7, 136.3, 139.6, 141.3, 141.8. ESI TOF MS: m/z 
[M+H]+ calcd. for 1474.8425, found 1475.7655. 
4.2.2.7. 2nd Generation aminoalcohol-triamine dendrimer 
gadolinium complex (Gd-4 (racemic)) 
A solution of GdCl3·6H2O (82 mg, 225 µmol) in MeOH (2.0 
mL) was added dropwise to a solution of 4 (racemic) (130 mg, 
226 µmol) in MeOH (3.0 mL), and the mixture was refluxed 
under argon for 48 h. The solvent was removed under reduced 
pressure to give 160 mg (190 µmol) of Gd-4 (racemic) as a 
yellow solid. 
4.2.3. Synthesis of Boc-Protected Dendrimer-triamine-
coordinated Gd-MRI CA (Gd-4-Boc) (Scheme 3) 
(Boc)2O (39.8 mg, 42 µL, 181 µmol) and TEA (14.5 mg, 20 
µL, 143 µmol) was added dropwise to a solution of 4 (racemic) 
(47.0 mg, 31.9 µmol) in MeOH (10 mL), and the mixture was 
stirred at room temperature for 2 h. The solvent was removed 
under reduced pressure, and the residue was purified by flash 
column chromatography (SiO2, CHCl3 : MeOH = 10 : 1) to give 
54.0 mg (26.0 µmol, 81%) of 4-Boc (racemic) as a yellow solid.  
ESI TOF MS: m/z [M+H]+ calcd. for 2075.5980, found 
2076.7795. A solution of GdCl3·6H2O (9.60 mg, 26.0 µmol) in 
MeOH (2.0 mL) was added dropwise to a solution of 4-Boc (54.0 




























































































Scheme 3.  Synthesis of PEG-conjugated Gd complex, Gd-4a-PEG 
 7 
under argon for 48 h. The solvent was removed under reduced 
pressure to give 60.4 mg (25.6 µmol, 98%) of Gd-4-Boc as a 
yellow solid.  ESI TOF MS: m/z [M+H]+ calcd. for 2339.1980, 
found 2339.6185. 
4.2.4. Synthesis of PEG-Dendrimer-triamine-coordinated Gd-
MRI CA (Gd-4a-PEG) (Scheme 3) 
A solution of 4a (30.0 mg, 20.4 μmol) and NHS-PEG (Mw 
5,000, 10 mg, 2.0 μmol) in DMSO (1 mL) was stirred at room 
temperature for 24 h. The residue was subjected to GPC (SB-
803HQ, eluent: ultrapure water, current speed: 1.0 mL/min, 
column temperature: 40 °C). The solvent was removed by 
lyophilization to give a white solid. This white solid and (Boc)2O 
(1.3 mg, 6.0 µmol) in CH3CN (5.0 mL) were stirred at room 
temperature for 24 h. The solvent was removed under reduced 
pressure, ultrapure water was added and the precipitate was 
removed by filter. To filtrate, GdCl3·6H2O (4.00 mg, 11.0 µmol) 
and MeOH (2.0 mL) were added and refluxed under argon for 48 
h. The solvent was removed under reduced pressure to give 6.9 
mg (0.63 µmol) of Gd-4a-PEG as a white solid.   
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